Adaptive Biotechnologies (ADPT) Research & Development (2018 - 2026)

Adaptive Biotechnologies has disclosed Research & Development across 9 years of filings, most recently posting $23.6 million for Q1 2026.

• Research & Development for Q1 2026 came in at $23.6 million, down 2.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $93.2 million (down 3.84% YoY), and the FY2025 annual result was $93.8 million, down 8.92% from the prior year.
• Research & Development came in at $23.6 million for Q1 2026 at Adaptive Biotechnologies, up from $21.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $37.8 million in Q1 2022 to a low of $21.8 million in Q4 2025.
• The 5-year median for Research & Development is $28.5 million (2023), against an average of $28.5 million.
• Across the five-year window, Research & Development gained 12.04% in 2022 and dropped 21.35% in 2024, its largest moves.
• Adaptive Biotechnologies' Research & Development stood at $31.2 million in 2022, then slipped by 7.93% to $28.7 million in 2023, then dropped by 19.32% to $23.2 million in 2024, then dropped by 6.16% to $21.8 million in 2025, then rose by 8.55% to $23.6 million in 2026.
• The last three Research & Development figures came in at $23.6 million (Q1 2026), $21.8 million (Q4 2025), and $23.7 million (Q3 2025), per Business Quant data.